Bo Mohr Morberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bo Mohr Morberg has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Per Bech
University of Copenhagen
4 shared publications - Lene Wermuth
Department of Neurology, Odense University Hospital, University of Southern Denmark, Odense, Denmark
3 shared publications Ole Gredal
A Department of Neurology , Odense University Hospital, University of Southern Denmark , Odense , Denmark
3 shared publications- Anne Sofie Bøgh Malling
Department of Neurology, Odense University Hospital, University of Southern Denmark, Odense, Denmark
2 shared publications Bente Rona Jensen
Department of Neurology, Odense University Hospital, University of Southern Denmark, Odense
2 shared publicationsAnne Sofie Malling
Department of Neurology, Odense University Hospital, University of Southern Denmark, Odense
1 shared publication
Latest Publications
- Open Access
- 27 April 2026
- Published by Elsevier in Neuroimmunology Reports
- Vol. 9
Case report: Severe encephalopathy with reversible white matter changes after gabapentin and morphine use: A toxic-metabolic mimic of ADEM
- 27 April 2026
- Published by Elsevier in Neuroimmunology Reports
- Vol. 9
Open AccessCase report: Severe encephalopathy with reversible white matter changes after gabapentin and morphine use: A toxic-metabolic mimic of ADEM
- 18 August 2018
- Published by Taylor & Francis in Nordic Journal of Psychiatry
- Vol. 72 (6) , 442-446
The Hawthorne effect as a pre-placebo expectation in Parkinsons disease patients participating in a randomized placebo-controlled clinical study
Background: The Hawthorne effect on clinical studies in Parkinson’s disease has not been thoroughly investigated. Evidently the Hawthorne effect may have impact on study outcomes acting as a ‘pre-placebo’ effect in the recruitment phase, hence before inclusion. Aim: The aim of this study was to discuss the Hawthorne effect in relation to clinical and self-reported outcome measures in a randomized clinical study in the recruitment phase and during the study. Methods: Data from 97 participants with Parkinson’s disease treated with Transcranial Pulsed Electromagnetic Fields were applied, randomized to an active (n = 49) or a placebo treated group (n = 48). The participants received one home treatment session, for eight consecutive weeks. Outcome measures were the Unified Parkinson’s Disease Rating Scale, The 39-item Parkinson’s Disease Questionnaire and the WHO-5. Results: No difference in treatment effect between the two groups was found pertaining the Unified Parkinson’s Disease Rating Scale. No difference in treatment effect between the two groups was found pertaining the 39-item Parkinson’s Disease Questionnaire, apart from the dimension mobility. No difference in treatment effect between the two groups was found pertaining the WHO-5 scale. Conclusions: The Hawthorne effect may have caused a ‘pre-placebo’ effect on the outcome measures even before obtaining baseline outcomes measures. This study may have been particularly prone to a Hawthorne effect due to the intense contact with the participants before and during the study. Moreover, the Hawthorne effect should not be viewed upon as a single entity but rather as entities affecting outcome measures throughout the full study period.
- 18 August 2018
- Published by Taylor & Francis in Nordic Journal of Psychiatry
- Vol. 72 (6) , 442-446
The Hawthorne effect as a pre-placebo expectation in Parkinsons disease patients participating in a randomized placebo-controlled clinical study
Background: The Hawthorne effect on clinical studies in Parkinson’s disease has not been thoroughly investigated. Evidently the Hawthorne effect may have impact on study outcomes acting as a ‘pre-placebo’ effect in the recruitment phase, hence before inclusion. Aim: The aim of this study was to discuss the Hawthorne effect in relation to clinical and self-reported outcome measures in a randomized clinical study in the recruitment phase and during the study. Methods: Data from 97 participants with Parkinson’s disease treated with Transcranial Pulsed Electromagnetic Fields were applied, randomized to an active (n = 49) or a placebo treated group (n = 48). The participants received one home treatment session, for eight consecutive weeks. Outcome measures were the Unified Parkinson’s Disease Rating Scale, The 39-item Parkinson’s Disease Questionnaire and the WHO-5. Results: No difference in treatment effect between the two groups was found pertaining the Unified Parkinson’s Disease Rating Scale. No difference in treatment effect between the two groups was found pertaining the 39-item Parkinson’s Disease Questionnaire, apart from the dimension mobility. No difference in treatment effect between the two groups was found pertaining the WHO-5 scale. Conclusions: The Hawthorne effect may have caused a ‘pre-placebo’ effect on the outcome measures even before obtaining baseline outcomes measures. This study may have been particularly prone to a Hawthorne effect due to the intense contact with the participants before and during the study. Moreover, the Hawthorne effect should not be viewed upon as a single entity but rather as entities affecting outcome measures throughout the full study period.
- 23 March 2018
- Published by Wiley in European Journal of Neurology
- Vol. 25 (7) , 963-+
Effects of transcranial pulsed electromagnetic field stimulation on quality of life in Parkinson's disease
Background and purpose: Pulsed electromagnetic fields induce a protective and anti‐inflammatory effect in the nervous system primarily due to growth factor upregulation that possibly abates neurodegeneration in Parkinson's disease (PD). This study investigated treatment effects of transcranial pulsed electromagnetic fields (T‐PEMFs) on quality of life in PD and the feasibility and safety of this treatment.Methods: In this double‐blinded clinical study, 97 participants with idiopathic PD (Hoehn & Yahr stage I–IV), on optimal medical anti‐parkinsonian treatment, were block randomized (3:3) to either active (n = 49) or placebo treatment (n = 48). Treatment with T‐PEMFs entailed one daily 30‐min home treatment for eight consecutive weeks. The 39‐item Parkinson's Disease Questionnaire (PDQ‐39) was assessed at baseline and endpoint. A special questionnaire was used to profile adverse events by interviewing the participants over the full treatment period. Treatment compliance was accounted for by daily treatment registration.Results: The active group improved with respect to clinical effect size for the two dimensions, i.e. mobility and activities of daily living, compared with the placebo group. No between‐group differences were found for the remaining PDQ‐39 dimensions. There were no between‐group difference in adverse events. Treatment compliance was 97.9%.Conclusion: Treatment with T‐PEMFs improved mobility and activities of daily living scores for clinical effect size only in the active group, indicating a positive treatment response for motor symptoms. No difference was found between the two groups for the remaining PDQ‐39 dimensions. The treatment had no or only mild adverse events and was performed with high compliance.
- 23 March 2018
- Published by Wiley in European Journal of Neurology
- Vol. 25 (7) , 963-+
Effects of transcranial pulsed electromagnetic field stimulation on quality of life in Parkinson's disease
Background and purpose: Pulsed electromagnetic fields induce a protective and anti‐inflammatory effect in the nervous system primarily due to growth factor upregulation that possibly abates neurodegeneration in Parkinson's disease (PD). This study investigated treatment effects of transcranial pulsed electromagnetic fields (T‐PEMFs) on quality of life in PD and the feasibility and safety of this treatment.Methods: In this double‐blinded clinical study, 97 participants with idiopathic PD (Hoehn & Yahr stage I–IV), on optimal medical anti‐parkinsonian treatment, were block randomized (3:3) to either active (n = 49) or placebo treatment (n = 48). Treatment with T‐PEMFs entailed one daily 30‐min home treatment for eight consecutive weeks. The 39‐item Parkinson's Disease Questionnaire (PDQ‐39) was assessed at baseline and endpoint. A special questionnaire was used to profile adverse events by interviewing the participants over the full treatment period. Treatment compliance was accounted for by daily treatment registration.Results: The active group improved with respect to clinical effect size for the two dimensions, i.e. mobility and activities of daily living, compared with the placebo group. No between‐group differences were found for the remaining PDQ‐39 dimensions. There were no between‐group difference in adverse events. Treatment compliance was 97.9%.Conclusion: Treatment with T‐PEMFs improved mobility and activities of daily living scores for clinical effect size only in the active group, indicating a positive treatment response for motor symptoms. No difference was found between the two groups for the remaining PDQ‐39 dimensions. The treatment had no or only mild adverse events and was performed with high compliance.
- 1 February 2018
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 81, 131-137
Evaluating psychiatric symptoms in Parkinson's Disease by a clinimetric analysis of the Hopkins Symptom Checklist (SCL-90-R)
- 1 February 2018
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 81, 131-137
Evaluating psychiatric symptoms in Parkinson's Disease by a clinimetric analysis of the Hopkins Symptom Checklist (SCL-90-R)
- 24 January 2017
- Published by Wiley in Movement Disorders
- Vol. 32 (4) , 625-626
Parkinson's disease and transcranial pulsed electromagnetic fields: A randomized clinical trial
- 24 January 2017
- Published by Wiley in Movement Disorders
- Vol. 32 (4) , 625-626
Parkinson's disease and transcranial pulsed electromagnetic fields: A randomized clinical trial